Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein

Seo, Tae Seok; Song, Myung Gyu; Kim, Jun Suk; Choi, Chul Won; Seo, Jae Hong; Oh, Sang Cheul; Kang, Eun Joo; Lee, Jae Kwan; Lee, Sung Yong

doi:10.5301/jva.5000751

Cited by 16 publications

(24 citation statements)

References 28 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26] In our study, the overall rate of complication 10.00% was lower than which in previous reports. [7,[27][28][29] Our study showed that chemotherapeutic drugs transfusion was safe on the TIVAP implantation day.…”

Section: Discussionmentioning

confidence: 56%

Clinical application of totally implantable venous access ports in patients with breast cancer

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Totally implantable venous access port (TIVAP) has become an effective approach for venous access chemotherapy in cancer treatment. We aimed to show the important procedures of clinical application of TIVAP and complications management in breast cancer.Patients and Methods From January 2013 to December 2017, patients with breast cancer who took TIVAP operation were investigated. The key procedures of TIVAP conduct and its complications were evaluated in this study.Results One hundred and ten ports were applied to 110 patients with breast cancer. All ports were successfully implanted in all patients including 108 male and 2 male patients. Patients were followed for an average of 275 days. Conclusion It is safe and effective of TIVAP implantation by blind puncture applied in patients with breast cancer. Chemotherapeutic drugs delivery on the placement day seems safe and showed no more complications.

show abstract

Section: Discussionmentioning

confidence: 56%

Clinical application of totally implantable venous access ports in patients with breast cancer

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The methods of TIVADs implantation mainly include venous cutdown and venous puncture [12] . At present, percutaneous puncture for TIVADs implantation via IJV and SCV are the most widely used [4] .…”

Section: Discussionmentioning

confidence: 99%

Comparison between Ultrasound-guided TIVAD via the right innominate vein and the right internal jugular vein approach

Sun

Bai

Shen

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose: To compare the efficacy and safety of right internal jugular vein (IJV) approach and right innominate vein (INV) approach for US-guided totally implantable venous access devices (TIVADs), and to explore the advantages and disadvantages of the two approaches. Methods: Six hundred and nineteen adult patients had long-term infusion and chemotherapy needs and inconvenience of peripheral venous infusion. Right INV approach was used to implant 339 cases of TIVADs, and right IJV approach was used to implant 280 cases of TIVADs. The success rate of one-time catheterization and the incidence of complications in the two groups were retrospectively analyzed. Results: All patients were successfully implanted in TIVAD. The success rates of one-time puncture in INV group and IJV approach group were 98.53% (334/339) and 95.36% (267/280), respectively. There was significant difference between the two groups (P=0.020). The incidence of perioperative complications was 1.18% (4/339) and the long-term complications was 3.54% (12/339) in the right INV group. The incidence of perioperative complications was 1.43% (4/280) and the long-term complications was 3.93% (11/280) in the right INV group. There was no significant difference in the incidence of complications between the two groups (P=0.785，P=0.799, respectively). Conclusions: US-guided TIVADs via the right INV approach and the right IJV approach are both safe and reliable. The right INV approach improves the one-time puncture success rate, as long as the technique is properly operated, serious complications rarely occur.

show abstract

“…Twenty-one 7,8,20,22,25,36,39,41,42,48,55,61,64,68,69,71,75,76,92,94,95 of the 69 noncomparison studies (23 cohorts, n = 12 265) reported VTE by number of thrombosis per 1000 catheter-days. Within these studies, the pooled rate of VTE was 0.08 (95% CI: 0.06-0.10) per 1000 catheter-days ( Figure S2).…”

Section: The Incidence Of Tivap-related Vtementioning

confidence: 99%

Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta‐analysis

Jiang

Pan

et al. 2020

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background Totally implantable venous access ports (TIVAPs) for chemotherapy are associated with venous thromboembolism (VTE). We aimed to quantify the incidence of TIVAP‐associated VTE and compare it with external central venous catheters (CVCs) in cancer patients through a meta‐analysis. Methods Studies reporting on VTE risk associated with TIVAP were retrieved from medical literature databases. In publications without a comparison group, the pooled incidence of TIVAP‐related VTE was calculated. For studies comparing TIVAPs with external CVCs, odds ratios (ORs) were calculated to assess the risk of VTE. Results In total, 80 studies (11 with a comparison group and 69 without) including 39 148 patients were retrieved. In the noncomparison studies, the overall symptomatic VTE incidence was 2.76% (95% confidence interval [CI]: 2.24‐3.28), and 0.08 (95 CI: 0.06‐0.10) per 1000 catheter‐days. This risk was highest when TIVAPs were inserted via the upper‐extremity vein (3.54%, 95% CI: 2.94‐4.76). Our meta‐analysis of the case‐control studies showed that TIVAPs were associated with a decreased risk of VTE compared with peripherally inserted central catheters (OR = 0.20, 95% CI: 0.09‐0.43), and a trend for lower VTE risk compared with Hickman catheters (OR = 0.75, 95% CI: 0.37‐1.50). Meta‐regression models suggested that regional difference may significantly impact on the incidence of VTE associated with TIVAPs. Conclusions Current evidence suggests that the cancer patients with TIVAP are less likely to develop VTE compared with external CVCs. This should be considered when choosing the indwelling intravenous device for chemotherapy. However, more attention should be paid when choosing upper‐extremity veins as the insertion site.

show abstract

Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein

Abstract: A single-incision technique for TIVAP implantation via the axillary vein seems to be safe with a low risk of complication.

Cited by 16 publications

References 28 publications

Clinical application of totally implantable venous access ports in patients with breast cancer

Clinical application of totally implantable venous access ports in patients with breast cancer

Comparison between Ultrasound-guided TIVAD via the right innominate vein and the right internal jugular vein approach

Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta‐analysis

Contact Info

Product

Resources

About